



**In just five years**

**NEOCODEX HAS CONSOLIDATED ITS POSITION IN THE USA  
AND LOOKS INTO THE POSSIBILITY OF ESTABLISHING  
ITSELF IN TOKYO**

**Neocodex is a genomics research company working within the biomedical field. Through biomedical research the company develops new diagnostic and therapeutic tools applicable to human health. It entered the USA market one year ago with the creation of Neocodex USA and is currently looking into the possibility of establishing itself in Tokyo.**

Madrid, 6 June 2007

Neocodex established a subsidiary company, Neocodex USA, in the USA (Indianapolis) one year ago, with the aim of positioning closer to the market all those developments achieved at its Spanish premises which had not generated the interest expected within Spain. This lack of interest may be due to delays in scientific progress within the Spanish context. With the creation of Neocodex USA, the company has broadened its horizons, working in partnership with institutions from the biotechnological sector and coming together the benefits of patent development with experience in other specific sectors in this industry.

During its first year of operations in the USA (Indianapolis), Neocodex has aroused interest in other pharmaceutical and biotechnological clusters, as is the case with Philadelphia, where there are more than 15 large pharmaceutical companies, seven of which are headquarters, and more than 400 biotechnological companies. In the latest BIO International Convention held in Boston, Neocodex held meetings with the most important officers from the Select Greater Philadelphia team. Philadelphia is one of the USA's most important business sectors for biotechnological development alongside Boston on the East coast and California on the West coast. The meetings were held to look at the possibility of reaching agreements to transfer the Neocodex headquarters from Indianapolis to Philadelphia.

Neocodex, along with the prestigious researcher Manuel Perucho, who has recently joined Neocodex as a scientific advisor, are assessing and studying the possibility of establishing Neocodex in Japan, with the objective of resolving one of the greatest research problems at present: the interpretation of the enormous variety of genetic data produced by different mass genome studies performed throughout the world. For this purpose, Neocodex has a patent called HFCC (Hypothesis Free Clinical Cloning), whose approval will help interpret and bring together better results than those obtained via traditional methods, which no longer produce the desired results within the international scientific community. It allows the more rational interpretation of millions of genetic markers, drastically reducing the analysis time in whole genome research, while also offering great precision and employing far fewer individuals in the studies, thus



significantly reducing the cost by more than 70%. It allows 100,000 markers to be analysed simultaneously in less than five seconds, reaching speeds greater than two million two hundred thousand comparisons per second.

Neocodex currently owns seven patents within the biomedical field, including the previously mentioned HFCC as well as others for cardiovascular risk, osteoporosis processes, menopause and pharmacogenetics. The company, which is located in Seville, currently owns 10% of biomedical patents in Andalusia and hopes to increase this figure to 50% within the next two years.

Neocodex is a biomedical genomics research company whose objective is to identify the genetic and molecular bases of diseases which are common in humans. Neocodex has grown and has become a leading company in biomedical research and development. In its endeavours to discover how genetic factors have an influence on the appearance and development of certain diseases, Neocodex leads research into genetic biomarkers by applying mass genome study methods. With a group of internationally recognised scientists, focusing on discovering and applying these discoveries to help explain complex diseases, Neocodex has been a pioneer in its integral approach to research projects within the biomedical field.